GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia

NCT01345253 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

709

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: Belimumab
DRUG: Placebo

Sponsor

GlaxoSmithKline

Collaborators

[object Object]